Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20091088 | 0.95 | OPRM1 (0.47) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL19523042 | 0.93 | OPRM1 (0.48) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18923583 | 0.89 | OPRM1 (0.44) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL28099989 | 0.87 | HDAC4 (0.42) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL7906262 | 0.82 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL16954110 | 0.82 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL15500995 | 0.81 | PNMT (0.47) | PNMTAOC3KMT2AALDH1A1HPGD | |
| SCHEMBL22169024 | 0.81 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL199109 | 0.81 | HDAC4 (0.53) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL26239181 | 0.81 | HDAC4 (0.53) | OPRM1OPRD1OPRK1OPRL1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2007006547-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | OPRM1 269/4885OPRD1 266/4885OPRK1 164/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | OPRM1 269/4885OPRD1 266/4885OPRK1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.